Novartis (NVS) announced that it had achieved positive results from its phase 3 study using its drug Kisqali with endocrine therapy to treat women with postmenopausal advanced breast cancer. There is a significant need for new treatments for these patients because over the years, the 5-year survival rate has not budged much despite some advancements.
On top of that, this is the second positive phase 3 study for Kisqali for women with advanced breast cancer. The first study is known as MONALEESA-7 and it recruited premenopausal women with hormone receptor-positive, HER2-negative advanced breast